<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Frantz, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hilary M DuBrock, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jess Mandel, MD, MACP, ATSF, FRCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joyce S Lee, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 16, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with pulmonary hypertension (PH) due to chronic lung disease (eg, chronic obstructive pulmonary disease, interstitial lung disease, or overlap syndromes) or conditions that cause hypoxemia (eg, obstructive sleep apnea, alveolar hypoventilation disorders) are classified as having group 3 PH  (<a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">table 1</a>).</p><p>The treatment and prognosis of patients with group 3 PH are reviewed here. The prevalence, pathogenesis, and diagnostic evaluation of patients with suspected group 3 PH are presented separately. (See  <a class="medical medical_review" href="/z/d/html/8262.html" rel="external">"Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Epidemiology, pathogenesis, and diagnostic evaluation in adults"</a>.)</p><p>Our approach is for the most part similar to that outlined in several society guidelines [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>The World Health Organization (WHO) classifies patients with PH into five groups based upon etiology [<a href="#rid2">2</a>]. Patients in group 1 are considered to have pulmonary <strong>arterial</strong> hypertension (also sometimes referred to as precapillary PH), whereas patients in group 2 (due to left-sided heart disease), group 3 (due to lung disorders and hypoxemia), group 4 (due to pulmonary artery obstructions), and group 5 (associated with different or mixed mechanisms) are considered to have PH  (<a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">table 1</a>). When all five groups are discussed collectively, the term PH is generally used. Classification of PH is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Postdiagnostic testing and classification'</a>.)</p><p>Group 3 PH can be caused by several lung disorders including:</p><p class="bulletIndent1"><span class="glyph">●</span>Obstructive lung disease (eg, chronic obstructive pulmonary disease or bronchiectasis)</p><p class="bulletIndent1"><span class="glyph">●</span>Restrictive lung disease (eg, interstitial lung disease, kyphoscoliosis)</p><p class="bulletIndent1"><span class="glyph">●</span>Other lung disease with mixed obstruction and restriction (eg, pulmonary fibrosis with emphysema)</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoxia without lung disease (eg, high altitude, sleep-disordered breathing, obesity hypoventilation)</p><p class="bulletIndent1"><span class="glyph">●</span>Developmental lung disorders (eg, bronchopulmonary dysplasia, congenital lobar emphysema)</p><p></p><p class="headingAnchor" id="H1388609340"><span class="h1">GENERAL MEASURES</span></p><p class="headingAnchor" id="H877514495"><span class="h2">Treatment of underlying condition</span><span class="headingEndMark"> — </span>Treatment of the underlying condition (eg, chronic obstructive pulmonary disease [COPD], interstitial lung disease, sleep-disordered breathing) is indicated in all patients with group 3 PH. However, while some strategies (eg, continuous positive airway pressure) modestly reduce pulmonary artery pressures (PAP), evidence to suggest significant reductions in PH or improved clinically impactful outcomes (eg, reduced mortality, improved exercise capacity, delayed progression) is lacking [<a href="#rid3">3-5</a>]. Nonetheless, disease-specific therapies are assumed to result in improved alveolar hypoxia, which is thought to contribute to the pathogenesis of PH and to progression of PH. For patients with high altitude PH, re-exposure to normal inspired oxygen tension is appropriate. (See  <a class="medical medical_review" href="/z/d/html/8262.html" rel="external">"Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Epidemiology, pathogenesis, and diagnostic evaluation in adults", section on 'Pathogenesis'</a>.)</p><p>Treatment of the underlying conditions are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">"Treatment of idiopathic pulmonary fibrosis"</a> and  <a class="medical medical_review" href="/z/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management"</a> and  <a class="medical medical_review" href="/z/d/html/7695.html" rel="external">"Obstructive sleep apnea: Overview of management in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7705.html" rel="external">"Obstructive sleep apnea and cardiovascular disease in adults", section on 'Impact of treatment'</a>.)</p><p class="headingAnchor" id="H2188407194"><span class="h2">Conventional and supportive therapies</span><span class="headingEndMark"> — </span>Similar to patients with group 1 pulmonary arterial hypertension (PAH), all patients with group 3 PH should exercise as tolerated, receive routine vaccinations  (<a class="graphic graphic_figure graphicRef62130" href="/z/d/graphic/62130.html" rel="external">figure 1</a>), be counselled against smoking, and be treated with supportive measures including oxygen and diuretics, when indicated. With the exception of oxygen, evidence to support the use of these therapies is typically extrapolated from patients with other forms of PH, the details of which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3884.html" rel="external">"Standard immunizations for nonpregnant adults"</a> and  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2786.html" rel="external">"The benefits and risks of aerobic exercise"</a> and  <a class="medical medical_review" href="/z/d/html/1463.html" rel="external">"Pulmonary rehabilitation"</a> and  <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'General measures and supportive therapy'</a>.)</p><p>Details regarding the care of select PH populations including patients who are considering pregnancy or who are pregnant, patients who are planning to travel or be exposed to high altitude, and patients requiring surgery are also discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'Special populations'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise, cessation of smoking, vaccination</strong> – The importance of regular exercise, cessation of smoking, and vaccination are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3884.html" rel="external">"Standard immunizations for nonpregnant adults"</a> and  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2786.html" rel="external">"The benefits and risks of aerobic exercise"</a> and  <a class="medical medical_review" href="/z/d/html/1463.html" rel="external">"Pulmonary rehabilitation"</a> and  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a> and  <a class="medical medical_review" href="/z/d/html/16635.html" rel="external">"Pharmacotherapy for smoking cessation in adults"</a> and  <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'General measures and supportive therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oxygen</strong> – Supplemental oxygen is typically prescribed for patients in group 3 PH who have hypoxemia (at rest or during exercise or sleep) with a goal of maintaining a peripheral oxygen saturation between 90 and 96 percent [<a href="#rid6">6</a>]. Supplemental oxygen, however, has only been documented to improve survival  (<a class="graphic graphic_figure graphicRef67353" href="/z/d/graphic/67353.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef82598" href="/z/d/graphic/82598.html" rel="external">figure 3</a>) and pulmonary vascular resistance in patients with COPD-associated PH who also have documented hypoxemia (ie, a partial arterial pressure of oxygen [PaO<sub>2</sub>] below 60 mmHg) [<a href="#rid7">7-12</a>]. In contrast, oxygen appears not to benefit those who are normoxemic [<a href="#rid13">13</a>]. Indications for supplemental oxygen are described in the table  (<a class="graphic graphic_table graphicRef76543" href="/z/d/graphic/76543.html" rel="external">table 2</a>). Evidence that describes benefit from supplemental oxygen in COPD are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">"Long-term supplemental oxygen therapy", section on 'Benefits'</a>.)</p><p></p><p class="bulletIndent1">It is inferred that supplemental oxygen may benefit other groups of patients with group 3 PH and hypoxemia, based upon data derived from patients with COPD and the rationale that oxygen may be beneficial by reducing hypoxic vasoconstriction, right ventricle (RV) afterload and/or pulmonary vascular remodeling. (See  <a class="medical medical_review" href="/z/d/html/8262.html" rel="external">"Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Epidemiology, pathogenesis, and diagnostic evaluation in adults", section on 'Pathogenesis'</a>.)</p><p></p><p class="bulletIndent1">In our experience, some patients with chronic hypoxemia demonstrate a marked reduction in PAP with continuous oxygen therapy while others have mild or moderate reductions. Predictors of a long-term response to supplemental oxygen include a decrease of the mean PAP greater than 5 mmHg and a high peak oxygen consumption (VO<sub>2</sub>) during exercise (&gt;6.5 cc/kg per minute) [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1">For patients with high altitude PH, re-exposure to normal inspired oxygen tension is appropriate, ie, administration of supplemental oxygen and/or descent to lower altitude.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diuretics</strong> – Patients with fluid retention from PH-related RV failure may benefit from diuretics. However, their administration is associated with some risk in patients with PH, the details of which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'General measures and supportive therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticoagulation</strong> – Anticoagulation is not typically administered to those with group 3 PH, although practice varies among centers and there are no data specific to this group that suggest benefit or harm associated with anticoagulation. Anticoagulation (typically with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>) in other PH populations (eg, group 4) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">"Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy", section on 'Anticoagulant therapy (indefinite)'</a> and  <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'General measures and supportive therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inotropic agents</strong> – <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">Digoxin</a> is an oral cardiac glycoside with inotropic effects that provides symptomatic benefit to patients with left ventricle (LV) systolic dysfunction; however, it is not typically indicated for the treatment of group 3 PH in the absence of coexisting atrial fibrillation or LV dysfunction based upon the rationale that outside of these indications, it has unproven benefit and may have adverse effects [<a href="#rid15">15-17</a>]. Among the potential detrimental effects, digoxin may induce pulmonary vasoconstriction and worsening PH [<a href="#rid18">18</a>]. In addition, the risk of digoxin toxicity is increased in the setting of hypoxemia and diuretic-induced hypokalemia. The administration of other inotropic agents in the acute setting is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">"Use of vasopressors and inotropes"</a> and  <a class="medical medical_review" href="/z/d/html/3488.html" rel="external">"Inotropic agents in heart failure with reduced ejection fraction"</a>.)</p><p></p><p class="headingAnchor" id="H272449166"><span class="h1">OUR APPROACH</span><span class="headingEndMark"> — </span>The treatment approach used by most experts is based upon data derived from small case series of patients with group 3 PH and data extrapolated from larger randomized trials performed in patients with group 1 pulmonary arterial hypertension (PAH). Unlike patients with PAH, we do not use the World Health Organization (WHO) functional classes to stratify patients  (<a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">table 3</a>) for therapy since functional class may be affected by both PH and the underlying lung disorder. Rather, we stratify patients based upon the severity of associated PH and severity of right ventricular (RV) failure (eg, elevated right atrial pressure, low cardiac index) and echocardiographic findings of impaired RV function. Among patients with chronic lung disease, PH is categorized as nonsevere (pulmonary vascular resistance [PVR] ≤5 Wood units [WU]) or severe (PVR &gt;5 WU) based on pulmonary hemodynamic findings from right heart catheterization (RHC) since this threshold has prognostic significance [<a href="#rid1">1</a>]. While there is a consensus definition for severe PH on RHC [<a href="#rid1">1</a>], definitions for mild or moderate PH on RHC and severity of PH on echocardiography are less well defined. Values used in the sections below are based upon our clinical experience and society guidelines.</p><p class="headingAnchor" id="H1758864688"><span class="h2">Nonsevere pulmonary hypertension</span><span class="headingEndMark"> — </span>Patients in this category include those with mild to moderate PH as estimated by echocardiography (eg, estimated systolic pulmonary artery pressure [sPAP] between approximately 35 and 60 mmHg), those with PVR ≤5 WU on RHC, and those without symptoms of RV failure [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3021796544"><span class="h3">Observation</span><span class="headingEndMark"> — </span>Patients with lung disorders and/or hypoxemia who have nonsevere PH typically require general supportive measures only (see <a class="local">'General measures'</a> above). All patients with nonsevere PH should be closely monitored every 6 to 12 months for the signs and symptoms of progressive PH. Clinical and echocardiographic findings indicative of development of RV failure are particularly important since these patients have a worse prognosis and may be more likely to respond to PH-specific therapy. It is sometimes challenging to distinguish progressive symptoms due to underlying lung disease from symptoms due to PH such that referral to a center with PH expertise should be performed where additional investigations can be done to help with this distinction. (See  <a class="medical medical_review" href="/z/d/html/8262.html" rel="external">"Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Epidemiology, pathogenesis, and diagnostic evaluation in adults"</a>.)</p><p class="headingAnchor" id="H3651845960"><span class="h2">Severe pulmonary hypertension</span><span class="headingEndMark"> — </span>Patients in this category include those with severe PH as estimated by echocardiography (eg, estimated sPAP ≥50 mmHg) or by RHC (PVR &gt;5 WU or patients with elevated mean PAP ≥25 mmHg with elevated right atrial pressure and/or low cardiac index &lt;2 liters/minute/meter<sup>2</sup>) [<a href="#rid1">1,19</a>]. Most patients in this category are treated with general measures (see <a class="local">'General measures'</a> above) and, <strong>unlike</strong> patients with group 1 PAH, are <strong>not</strong> typically treated with PAH-directed therapy with the exception of PH associated with interstitial lung disease (ILD). Patients with severe PH should be referred to a specialized center for further evaluation and management and for potential inclusion in clinical trials. (See <a class="local">'Pulmonary arterial hypertension-directed therapy'</a> below.)</p><p class="headingAnchor" id="H4011303759"><span class="h3">Pulmonary arterial hypertension-directed therapy</span><span class="headingEndMark"> — </span>Pharmacologic agents used for PAH-directed therapy include prostacyclin pathway agents (eg, <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a>, <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a>, <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">iloprost</a>, <a class="drug drug_general" data-topicid="106041" href="/z/d/drug information/106041.html" rel="external">selexipag</a>), phosphodiesterase-5 (PDE-5) inhibitors (eg, <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a>, <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a>), nitric oxide-cyclic guanosine monophosphate enhancers including soluble guanylate cyclase stimulators (<a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">riociguat</a>), and endothelin receptor antagonists (eg, <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a>, <a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">ambrisentan</a>, <a class="drug drug_general" data-topicid="91206" href="/z/d/drug information/91206.html" rel="external">macitentan</a>). While these agents have efficacy in the treatment of patients with group 1 PAH  (<a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">table 1</a>) (see  <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Definition'</a>), their efficacy in group 3 PH is limited and in some cases, may be harmful [<a href="#rid20">20</a>]. With the exception of inhaled treprostinil for PH associated with ILD, none of these agents have been approved for use in group 3 PH. The poor performance of PAH-directed therapy in this population may be partially explained by vasodilatory effects of these agents that may exacerbate ventilation-perfusion abnormalities and worsen gas exchange in patients with lung disease [<a href="#rid21">21-25</a>].</p><p>However, exceptions to this general rule exist. In rare circumstances PAH-directed therapy is considered for patients who are in RV failure with advanced WHO functional class III or IV symptoms  (<a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">table 3</a>) in whom general measures have failed and in whom a strong component of PH is thought to be unrelated to their lung disease (eg, severe PH and mild lung disease). This is particularly true for select patients with systemic sclerosis (SSc), in whom a vasculopathy similar to other forms of PAH is known to occur. In such cases, patients should be evaluated in the setting of a center with expertise in PH where extensive investigations can be conducted to distinguish patients with PAH (ie, group 1) who happen to have concomitant lung disease from patients with PH due to their lung disease (ie, true group 3 PH); such centers are also likely to be involved in suitable clinical trials for both of these populations. (See  <a class="medical medical_review" href="/z/d/html/8256.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H3633497702"><span class="h4">Chronic obstructive disease</span><span class="headingEndMark"> — </span>Several trials in patients with chronic obstructive pulmonary disease (COPD) have shown mixed effects of PAH-directed therapy on resting and exercise-induced pulmonary hemodynamics, six-minute walk distance (6MWD), and many have shown worsening oxygenation parameters and quality of life (QOL) [<a href="#rid26">26-37</a>]. Data have been described for the following agents:</p><p class="bulletIndent1"><span class="glyph">●</span>Prostacyclin pathway agents including prostacyclin and inhaled <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">iloprost</a> [<a href="#rid33">33-35</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PDE-5 inhibitors including <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a> [<a href="#rid26">26-29</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endothelin receptor antagonists including <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a> [<a href="#rid31">31</a>] and <a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">ambrisentan</a> [<a href="#rid32">32</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nitric oxide-cyclic guanosine monophosphate<strong> </strong>enhancers including <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">riociguat</a> [<a href="#rid37">37</a>] and <a class="drug drug_general" data-topicid="9447" href="/z/d/drug information/9447.html" rel="external">inhaled nitric oxide</a> [<a href="#rid36">36</a>]</p><p></p><p class="headingAnchor" id="H2541309026"><span class="h4">Interstitial lung disease</span><span class="headingEndMark"> — </span>There have been mixed results from PAH-directed therapy clinical trials in patients with ILD-related PH with some agents demonstrating benefit and others either no benefit or an increase in serious adverse events:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary fibrosis:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Parenteral prostanoids – Twelve weeks of parenteral <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a> has been shown to improve right atrial pressure, cardiac index, RV function, QOL, brain natriuretic peptide (BNP), and 6MWD in a case series of patients with pulmonary fibrosis and severe PH without any adverse effects on oxygenation [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inhaled <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a> – Inhaled delivery of prostanoids is attractive since there may be less potential for worsening of ventilation/perfusion mismatch than with oral or parenteral agents. In one multicenter randomized controlled trial (INCREASE) of 326 patients with ILD-related PH (mostly idiopathic pulmonary fibrosis [IPF], connective tissue disease (CTD), and combined pulmonary fibrosis and emphysema [CPFE]), 16 weeks of inhaled treprostinil resulted in a small improvement in the 6MWD compared with placebo (mean difference was 31 meters) [<a href="#rid39">39</a>]. In addition, inhaled treprostinil resulted in a reduction in N-terminal pro-BNP (15 percent reduction versus 46 percent increase in NT-proBNP levels) and reduced the proportion of patients who clinically deteriorated during the period of the trial (23 versus 33 percent).</p><p></p><p class="bulletIndent2">Higher doses were also associated with increased benefit [<a href="#rid40">40</a>]. In a post-hoc analysis of the INCREASE study, inhaled <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a> was also associated with improvements in forced vital capacity compared with placebo, particularly among patients with IPF [<a href="#rid41">41</a>]. The impact of treprostinil on the subgroup with CPFE was less robust than that on patients with IPF- and CTD-related ILD. Adverse effects were mild and included headache, cough, dyspnea, dizziness, nausea, fatigue, and diarrhea. Inhaled treprostinil has received regulatory approval for this indication [<a href="#rid42">42</a>]. Further studies are needed to help define patient subgroups who are most likely to respond.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>PDE-5 inhibitors – While <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a> is of limited or no benefit in patients with IPF who do not have PH [<a href="#rid43">43,44</a>], some studies suggest possible benefit in those with RV dysfunction [<a href="#rid45">45,46</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endothelin receptor antagonists and nitric oxide-cyclic guanosine monophosphate enhancers – <a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">Ambrisentan</a> has been shown in major trials to be ineffective and associated with adverse effects (eg, worsening oxygenation, disease progression, increased hospitalizations) in patients with PH due to IPF or other etiologies and IPF (without PH) [<a href="#rid32">32,47,48</a>]. <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">Bosentan</a> and <a class="drug drug_general" data-topicid="91206" href="/z/d/drug information/91206.html" rel="external">macitentan</a> are also ineffective in IPF but have not been tested in IPF-associated PH [<a href="#rid49">49-51</a>]. Although early studies suggested some benefit from <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">riociguat</a> [<a href="#rid52">52-54</a>], a phase II study in patients with idiopathic interstitial pneumonia-associated PH was terminated early due to an increase in drug-related adverse events and mortality [<a href="#rid48">48,55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SSc – Data describing the use of PAH-directed therapy in patients with SSc are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8256.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Others – PH in lymphangioleiomyomatosis is now also classified as group 3 PH given similarities to other chronic lung disease [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1">Although classified as belonging to group 5 PH, only case reports describe individual responses to therapy in rare ILDs, such as pulmonary Langerhans histiocytosis [<a href="#rid56">56-58</a>]. (See  <a class="medical medical_review" href="/z/d/html/4334.html" rel="external">"Pulmonary Langerhans cell histiocytosis"</a>.)</p><p></p><p class="bulletIndent1">Similarly, retrospective case series suggest some patients with sarcoidosis-associated PH (typically classified as group 5 PH) may experience improved functional class and hemodynamic parameters with the use of inhaled <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">iloprost</a>, <a class="drug drug_general" data-topicid="9447" href="/z/d/drug information/9447.html" rel="external">inhaled nitric oxide</a>, <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a>, <a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">ambrisentan</a>, <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a>, or combination therapy [<a href="#rid21">21,25,59-67</a>]. Most studies suggest marginal improvements in pulmonary hemodynamics with minimal or no effect on 6MWD, and some even reporting pulmonary edema, although the latter may have been due to the coexistence of pulmonary veno-occlusive disease. (See  <a class="medical medical_review" href="/z/d/html/132051.html" rel="external">"Sarcoidosis-associated pulmonary hypertension: Diagnostic evaluation in adults"</a> and  <a class="medical medical_review" href="/z/d/html/138414.html" rel="external">"Sarcoidosis-associated pulmonary hypertension: Treatment and prognosis in adults"</a>.)</p><p></p><p class="headingAnchor" id="H1139771397"><span class="h4">Sleep-disordered breathing and hypoxia</span><span class="headingEndMark"> — </span>Only case reports describe individual responses to therapy in rare diseases including kyphoscoliosis and obesity hypoventilation [<a href="#rid68">68,69</a>].</p><p class="headingAnchor" id="H1280297640"><span class="h4">Overlap syndromes</span><span class="headingEndMark"> — </span>Despite the poor prognosis of PH associated with overlap syndromes (eg, combined vascular and ILD, combined COPD and ILD), data are limited regarding the use of PAH-directed therapy in this population. (See  <a class="medical medical_review" href="/z/d/html/8256.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/8251.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Definition, risk factors, and screening"</a>.)</p><p class="headingAnchor" id="H3117170340"><span class="h2">Patients who fail therapy</span><span class="headingEndMark"> — </span>Patients with severe group 3 PH who fail therapy should be considered for lung transplantation. Other surgical measures have not been evaluated in this population (eg, atrial septostomy). (See  <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Right-to-left shunt'</a> and  <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Lung transplantation'</a>.)</p><p>In patients who fail therapy and are not candidates for lung transplantation, consideration of palliative care for assistance with symptom management is appropriate. (See  <a class="medical medical_review" href="/z/d/html/86307.html" rel="external">"Palliative care for adults with nonmalignant chronic lung disease"</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Lung transplantation</span><span class="headingEndMark"> — </span>Lung transplantation may be an option in patients with group 3 PH who progress despite therapy [<a href="#rid70">70</a>].</p><p>The effect of PH on lung transplantation outcome is uncertain [<a href="#rid71">71-76</a>]. Several studies suggest that PH does not adversely impact the survival of patients with ILD who undergo lung transplantation [<a href="#rid71">71-73</a>]. But registry data suggests that PH is a risk factor for 90-day mortality after single lung transplantation [<a href="#rid75">75</a>] and the presence of PH may confer a higher risk of primary graft dysfunction in patients undergoing transplantation for ILD [<a href="#rid77">77</a>].</p><p>While single lung transplantation without cardiopulmonary bypass is an option for most patients with chronic lung disease without PH [<a href="#rid72">72,73,78,79</a>] it may be less suitable for those with severe PH [<a href="#rid80">80-83</a>], where bilateral lung transplantation is usually preferred. Living lobar lung transplantation is also an option for a small number of patients [<a href="#rid78">78,84</a>]. (See  <a class="medical medical_review" href="/z/d/html/4659.html" rel="external">"Lung transplantation: An overview"</a> and  <a class="medical medical_review" href="/z/d/html/4660.html" rel="external">"Lung transplantation: Disease-based choice of procedure"</a> and  <a class="medical medical_review" href="/z/d/html/4656.html" rel="external">"Noninfectious complications following lung transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">"Lung transplantation: General guidelines for recipient selection"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>PH from underlying lung disease and/or hypoxemia is typically progressive and is generally associated with increased morbidity and mortality.</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic obstructive pulmonary disease (COPD) – Numerous trials have shown that PH negatively affects survival in COPD and that survival worsens with increasing PH severity [<a href="#rid85">85-91</a>].</p><p></p><p class="bulletIndent1">As an example, four-year survival is roughly 75 percent among patients with COPD of varying severity [<a href="#rid85">85</a>], but &lt;50 percent among patients whose COPD is complicated by PH [<a href="#rid86">86</a>]. Survival for longer than three years is rare among patients with COPD who have a pulmonary vascular resistance (PVR) &gt;550 dynes-sec-cm<sup>5</sup> (6.875 Wood units [WU]) [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent1">PH has also been shown to predict increased hospitalization in patients with COPD [<a href="#rid92">92</a>].</p><p></p><p class="bulletIndent1">Among different hemodynamic variables and thresholds, PVR &gt;5 WU was the strongest predictor of prognosis [<a href="#rid93">93</a>]. Severe reduction in the diffusing capacity for carbon monoxide (DLCO) is also associated with a high mortality [<a href="#rid94">94</a>], with one study reporting a 4 percent increase in the risk of death for every 1 percent reduction in DLCO percent predicted [<a href="#rid95">95</a>]. Other risk factors for death include male sex, poor exercise capacity, and high PVR [<a href="#rid91">91</a>]. Survival also appears to be worse in patients with COPD compared with patients with idiopathic pulmonary arterial hypertension (ie, group 1 disease) [<a href="#rid91">91</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interstitial lung disease (ILD) – Similarly, patients with ILD-related PH have a poorer prognosis than patients with ILD alone [<a href="#rid96">96-104</a>].</p><p></p><p class="bulletIndent1">In a retrospective study of 131 patients with idiopathic pulmonary fibrosis (IPF), patients with PH had a shorter median survival than patients without PH (11 versus 23 months) [<a href="#rid105">105</a>]. Moreover, mortality increases as the severity of the PH increases [<a href="#rid96">96,98</a>]. In another retrospective study of IPF patients survival correlated with PH severity with median survival estimates of 4.8 years in those with a systolic pulmonary artery pressure (sPAP) ≤35 mmHg, 4.1 years in those with a sPAP 36 to 50 mmHg, and 0.7 years in those with a sPAP &gt;50 mmHg [<a href="#rid98">98</a>]. Similar trends have been reported in those with sarcoidosis [<a href="#rid60">60,106</a>]. (See  <a class="medical medical_review" href="/z/d/html/138414.html" rel="external">"Sarcoidosis-associated pulmonary hypertension: Treatment and prognosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sleep-disordered breathing – The presence of PH may also have prognostic importance in patients with obstructive sleep apnea, the details of which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7705.html" rel="external">"Obstructive sleep apnea and cardiovascular disease in adults", section on 'Clinical evidence'</a>.)</p><p></p><p class="bulletIndent1">Similar poor outcomes in obesity hypoventilation have been reported where the presence of PH is associated with reduced exercise capacity, greater daytime sleepiness, and worse health-related quality of life [<a href="#rid4">4,107</a>].</p><p></p><p class="headingAnchor" id="H1034310709"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115503.html" rel="external">"Society guideline links: Pulmonary hypertension in adults"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – Patients with pulmonary hypertension (PH) associated with chronic lung disease (eg, chronic obstructive pulmonary disease, interstitial lung disease, or overlap syndromes) or conditions that cause hypoxemia (eg, obstructive sleep apnea, alveolar hypoventilation disorders) are classified as having group 3 PH  (<a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">table 1</a>). (See <a class="local">'Introduction'</a> above and <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General measures</strong> – While considerable variation exists among centers, we suggest that all patients be treated for their underlying lung disease, receive routine conventional therapies (eg, vaccination, counselled against smoking, exercise), and supportive therapies (when indicated; eg, oxygen, diuretics). Supplemental oxygen is typically prescribed for those with hypoxemia (at rest or during exercise or sleep) with a goal of maintaining a peripheral oxygen saturation greater than 90 percent. (See <a class="local">'General measures'</a> above and  <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">"Long-term supplemental oxygen therapy"</a> and  <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'General measures and supportive therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Our approach</strong> – Most patients with group 3 PH should be referred to a specialized center for evaluation. Our general approach is the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most patients – For most patients with group 3 PH, we recommend <strong>against</strong> treatment with pulmonary arterial hypertension (PAH)-directed therapy since it has not been shown to result in significant benefit and may be associated with harm (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonsevere PH – Patients with group 3 PH who have nonsevere PH should be closely monitored every 6 to 12 months for the signs and symptoms of progressive PH and right ventricular failure. (See <a class="local">'Nonsevere pulmonary hypertension'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe PH – Most patients with group 3 PH who have severe PH should be referred to a specialized center for potential inclusion in clinical trials. (See <a class="local">'Severe pulmonary hypertension'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Suspected component of PAH – Patients with a suspected component of group 1 PAH whose underlying lung disease does not explain the severity of PH, and some patients with severe right heart failure, may be eligible for PAH-directed therapies on a case-by-case basis, but caution is required due to the possibility of worsening oxygenation. All patients who receive PAH-directed therapy should be closely monitored for a treatment response.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who fail therapy – Patients with group 3 PH who progress despite therapy should be evaluated for lung transplantation. Other surgical measures have not been evaluated in this population (eg, atrial septostomy). (See <a class="local">'Lung transplantation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – PH associated with underlying lung disease and/or hypoxemia is typically progressive and is generally associated with increased morbidity and mortality. Mortality generally increases with the severity of PH. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H1312744787"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael McGoon, MD, and Jay H Ryu, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43:3618.</a></li><li><a class="nounderline abstract_t">Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53.</a></li><li><a class="nounderline abstract_t">Castro-Añón O, Golpe R, Pérez-de-Llano LA, et al. Haemodynamic effects of non-invasive ventilation in patients with obesity-hypoventilation syndrome. Respirology 2012; 17:1269.</a></li><li><a class="nounderline abstract_t">Kauppert CA, Dvorak I, Kollert F, et al. Pulmonary hypertension in obesity-hypoventilation syndrome. Respir Med 2013; 107:2061.</a></li><li><a class="nounderline abstract_t">Adir Y, Humbert M, Chaouat A. Sleep-related breathing disorders and pulmonary hypertension. Eur Respir J 2021; 57.</a></li><li><a class="nounderline abstract_t">Hoeper MM, Andreas S, Bastian A, et al. Pulmonary hypertension due to chronic lung disease: updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 2011; 154 Suppl 1:S45.</a></li><li><a class="nounderline abstract_t">Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1:681.</a></li><li><a class="nounderline abstract_t">Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93:391.</a></li><li><a class="nounderline abstract_t">Timms RM, Khaja FU, Williams GW. Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. Ann Intern Med 1985; 102:29.</a></li><li><a class="nounderline abstract_t">Weitzenblum E, Sautegeau A, Ehrhart M, et al. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985; 131:493.</a></li><li><a class="nounderline abstract_t">Sliwiński P, Hawrylkiewicz I, Górecka D, Zieliński J. Acute effect of oxygen on pulmonary arterial pressure does not predict survival on long-term oxygen therapy in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146:665.</a></li><li><a class="nounderline abstract_t">Selinger SR, Kennedy TP, Buescher P, et al. Effects of removing oxygen from patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1987; 136:85.</a></li><li><a class="nounderline abstract_t">Long-Term Oxygen Treatment Trial Research Group, Albert RK, Au DH, et al. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med 2016; 375:1617.</a></li><li><a class="nounderline abstract_t">Ashutosh K, Dunsky M. Noninvasive tests for responsiveness of pulmonary hypertension to oxygen. Prediction of survival in patients with chronic obstructive lung disease and cor pulmonale. Chest 1987; 92:393.</a></li><li><a class="nounderline abstract_t">Polić S, Rumboldt Z, Dujić Z, et al. Role of digoxin in right ventricular failure due to chronic cor pulmonale. Int J Clin Pharmacol Res 1990; 10:153.</a></li><li><a class="nounderline abstract_t">Mathur PN, Powles P, Pugsley SO, et al. Effect of digoxin on right ventricular function in severe chronic airflow obstruction. A controlled clinical trial. Ann Intern Med 1981; 95:283.</a></li><li><a class="nounderline abstract_t">McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol 2015; 65:1976.</a></li><li class="breakAll">Lee-Chiong TL, Matthay RA.. The heart in the stable COPD patient.. In: Clinical management of chronic obstructive pulmonary disease., Similowski T, Whitelaw WA, Derenne JP (Eds), Marcel Dekker, Inc., New York 2002. p.475.</li><li><a class="nounderline abstract_t">Seeger W, Adir Y, Barberà JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013; 62:D109.</a></li><li><a class="nounderline abstract_t">Rhee RL, Gabler NB, Praestgaard A, et al. Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. Arthritis Rheumatol 2015; 67:2457.</a></li><li><a class="nounderline abstract_t">Barnett CF, Bonura EJ, Nathan SD, et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest 2009; 135:1455.</a></li><li><a class="nounderline abstract_t">Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160:600.</a></li><li><a class="nounderline abstract_t">Strange C, Bolster M, Mazur J, et al. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest 2000; 118:1077.</a></li><li><a class="nounderline abstract_t">Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360:895.</a></li><li><a class="nounderline abstract_t">Fisher KA, Serlin DM, Wilson KC, et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006; 130:1481.</a></li><li><a class="nounderline abstract_t">Blanco I, Gimeno E, Munoz PA, et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010; 181:270.</a></li><li><a class="nounderline abstract_t">Blanco I, Santos S, Gea J, et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J 2013; 42:982.</a></li><li><a class="nounderline abstract_t">Rietema H, Holverda S, Bogaard HJ, et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 2008; 31:759.</a></li><li><a class="nounderline abstract_t">Lederer DJ, Bartels MN, Schluger NW, et al. Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD 2012; 9:268.</a></li><li><a class="nounderline abstract_t">Holverda S, Rietema H, Bogaard HJ, et al. Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. Pulm Pharmacol Ther 2008; 21:558.</a></li><li><a class="nounderline abstract_t">Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008; 32:619.</a></li><li><a class="nounderline abstract_t">Badesch DB, Feldman J, Keogh A, et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 2012; 30:93.</a></li><li><a class="nounderline abstract_t">Naeije R, Mélot C, Mols P, Hallemans R. Reduction in pulmonary hypertension by prostaglandin E1 in decompensated chronic obstructive pulmonary disease. Am Rev Respir Dis 1982; 125:1.</a></li><li><a class="nounderline abstract_t">Archer SL, Mike D, Crow J, et al. A placebo-controlled trial of prostacyclin in acute respiratory failure in COPD. Chest 1996; 109:750.</a></li><li><a class="nounderline abstract_t">Dernaika TA, Beavin M, Kinasewitz GT. Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respiration 2010; 79:377.</a></li><li><a class="nounderline abstract_t">Vonbank K, Ziesche R, Higenbottam TW, et al. Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD. Thorax 2003; 58:289.</a></li><li><a class="nounderline abstract_t">Ghofrani HA, Staehler G, Grünig E, et al. Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease. Pulm Circ 2015; 5:296.</a></li><li><a class="nounderline abstract_t">Saggar R, Khanna D, Vaidya A, et al. Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis. Thorax 2014; 69:123.</a></li><li><a class="nounderline abstract_t">Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. N Engl J Med 2021; 384:325.</a></li><li><a class="nounderline abstract_t">Nathan SD, Deng C, King CS, et al. Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes. Chest 2023; 163:398.</a></li><li><a class="nounderline abstract_t">Nathan SD, Waxman A, Rajagopal S, et al. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. Lancet Respir Med 2021; 9:1266.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/022387Orig1s017ltr.pdf (Accessed on April 02, 2021).</li><li><a class="nounderline abstract_t">Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363:620.</a></li><li><a class="nounderline abstract_t">Jackson RM, Glassberg MK, Ramos CF, et al. Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. Lung 2010; 188:115.</a></li><li><a class="nounderline abstract_t">Han MK, Bach DS, Hagan PG, et al. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest 2013; 143:1699.</a></li><li><a class="nounderline abstract_t">Zimmermann GS, von Wulffen W, Huppmann P, et al. Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors. Respirology 2014; 19:700.</a></li><li><a class="nounderline abstract_t">Raghu G, Nathan SD, Behr J, et al. Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. Eur Respir J 2015; 46:1370.</a></li><li><a class="nounderline abstract_t">Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013; 158:641.</a></li><li><a class="nounderline abstract_t">King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177:75.</a></li><li><a class="nounderline abstract_t">King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184:92.</a></li><li><a class="nounderline abstract_t">Raghu G, Million-Rousseau R, Morganti A, et al. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J 2013; 42:1622.</a></li><li><a class="nounderline abstract_t">Hoeper MM, Halank M, Wilkens H, et al. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur Respir J 2013; 41:853.</a></li><li><a class="nounderline abstract_t">Humbert M, Coghlan JG, Ghofrani HA, et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis 2017; 76:422.</a></li><li><a class="nounderline abstract_t">Ghofrani HA, Grimminger F, Grünig E, et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med 2016; 4:361.</a></li><li><a class="nounderline abstract_t">Nathan SD, Behr J, Collard HR, et al. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respir Med 2019; 7:780.</a></li><li><a class="nounderline abstract_t">Le Pavec J, Lorillon G, Jaïs X, et al. Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest 2012; 142:1150.</a></li><li><a class="nounderline abstract_t">Kiakouama L, Cottin V, Etienne-Mastroïanni B, et al. Severe pulmonary hypertension in histiocytosis X: long-term improvement with bosentan. Eur Respir J 2010; 36:202.</a></li><li><a class="nounderline abstract_t">Cottin V, Harari S, Humbert M, et al. Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. Eur Respir J 2012; 40:630.</a></li><li><a class="nounderline abstract_t">Bonham CA, Oldham JM, Gomberg-Maitland M, Vij R. Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series. Chest 2015; 148:1055.</a></li><li><a class="nounderline abstract_t">Keir GJ, Walsh SL, Gatzoulis MA, et al. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31:82.</a></li><li><a class="nounderline abstract_t">Baughman RP. Pulmonary hypertension associated with sarcoidosis. Arthritis Res Ther 2007; 9 Suppl 2:S8.</a></li><li><a class="nounderline abstract_t">Baughman RP, Judson MA, Lower EE, et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26:110.</a></li><li><a class="nounderline abstract_t">Baughman RP, Culver DA, Cordova FC, et al. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest 2014; 145:810.</a></li><li><a class="nounderline abstract_t">Preston IR, Klinger JR, Landzberg MJ, et al. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 2001; 120:866.</a></li><li><a class="nounderline abstract_t">Shapiro S, Pollock DM, Gillies H, et al. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan. Am J Cardiol 2012; 110:1373.</a></li><li><a class="nounderline abstract_t">Milman N, Burton CM, Iversen M, et al. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J Heart Lung Transplant 2008; 27:329.</a></li><li><a class="nounderline abstract_t">Boucly A, Cottin V, Nunes H, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J 2017; 50.</a></li><li><a class="nounderline abstract_t">Friedman SE, Andrus BW. Obesity and pulmonary hypertension: a review of pathophysiologic mechanisms. J Obes 2012; 2012:505274.</a></li><li><a class="nounderline abstract_t">Hosokawa Y, Yamamoto T, Yabuno Y, et al. Inhaled nitric oxide therapy for secondary pulmonary hypertension with hypertrophic obstructive cardiomyopathy and severe kyphoscoliosis. Int J Cardiol 2012; 158:e20.</a></li><li><a class="nounderline abstract_t">Leard LE, Holm AM, Valapour M, et al. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2021; 40:1349.</a></li><li><a class="nounderline abstract_t">Harari S, Simonneau G, De Juli E, et al. Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation. J Heart Lung Transplant 1997; 16:460.</a></li><li><a class="nounderline abstract_t">Huerd SS, Hodges TN, Grover FL, et al. Secondary pulmonary hypertension does not adversely affect outcome after single lung transplantation. J Thorac Cardiovasc Surg 2000; 119:458.</a></li><li><a class="nounderline abstract_t">Fitton TP, Kosowski TR, Barreiro CJ, et al. Impact of secondary pulmonary hypertension on lung transplant outcome. J Heart Lung Transplant 2005; 24:1254.</a></li><li><a class="nounderline abstract_t">Bando K, Keenan RJ, Paradis IL, et al. Impact of pulmonary hypertension on outcome after single-lung transplantation. Ann Thorac Surg 1994; 58:1336.</a></li><li><a class="nounderline abstract_t">Whelan TP, Dunitz JM, Kelly RF, et al. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant 2005; 24:1269.</a></li><li><a class="nounderline abstract_t">Hayes D Jr, Higgins RS, Black SM, et al. Effect of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis after lung transplantation: an analysis of the United Network of Organ Sharing registry. J Heart Lung Transplant 2015; 34:430.</a></li><li><a class="nounderline abstract_t">Fang A, Studer S, Kawut SM, et al. Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis. Chest 2011; 139:782.</a></li><li><a class="nounderline abstract_t">Alalawi R, Whelan T, Bajwa RS, Hodges TN. Lung transplantation and interstitial lung disease. Curr Opin Pulm Med 2005; 11:461.</a></li><li><a class="nounderline abstract_t">Conte JV, Borja MJ, Patel CB, et al. Lung transplantation for primary and secondary pulmonary hypertension. Ann Thorac Surg 2001; 72:1673.</a></li><li><a class="nounderline abstract_t">Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012; 31:1073.</a></li><li><a class="nounderline abstract_t">Gottlieb J. Lung transplantation for interstitial lung diseases and pulmonary hypertension. Semin Respir Crit Care Med 2013; 34:281.</a></li><li><a class="nounderline abstract_t">Puri V, Patterson GA, Meyers BF. Single versus bilateral lung transplantation: do guidelines exist? Thorac Surg Clin 2015; 25:47.</a></li><li><a class="nounderline abstract_t">Gottlieb J. Lung transplantation for interstitial lung diseases. Curr Opin Pulm Med 2014; 20:457.</a></li><li><a class="nounderline abstract_t">Lu BS, Bhorade SM. Lung transplantation for interstitial lung disease. Clin Chest Med 2004; 25:773.</a></li><li><a class="nounderline abstract_t">Yildiz OA, Onen ZP, Sen E, et al. Predictors of long-term survival in patients with chronic obstructive pulmonary disease. Saudi Med J 2006; 27:1866.</a></li><li><a class="nounderline abstract_t">Budev MM, Arroliga AC, Wiedemann HP, Matthay RA. Cor pulmonale: an overview. Semin Respir Crit Care Med 2003; 24:233.</a></li><li><a class="nounderline abstract_t">MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One. Am J Respir Crit Care Med 1994; 150:833.</a></li><li><a class="nounderline abstract_t">Hurdman J, Condliffe R, Elliot CA, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J 2013; 41:1292.</a></li><li><a class="nounderline abstract_t">Oswald-Mammosser M, Weitzenblum E, Quoix E, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995; 107:1193.</a></li><li><a class="nounderline abstract_t">Stone AC, Machan JT, Mazer J, et al. Echocardiographic evidence of pulmonary hypertension is associated with increased 1-year mortality in patients admitted with chronic obstructive pulmonary disease. Lung 2011; 189:207.</a></li><li><a class="nounderline abstract_t">Vizza CD, Hoeper MM, Huscher D, et al. Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Chest 2021; 160:678.</a></li><li><a class="nounderline abstract_t">Kessler R, Faller M, Fourgaut G, et al. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159:158.</a></li><li><a class="nounderline abstract_t">Zeder K, Avian A, Bachmaier G, et al. Elevated pulmonary vascular resistance predicts mortality in COPD patients. Eur Respir J 2021; 58.</a></li><li><a class="nounderline abstract_t">Rose L, Prins KW, Archer SL, et al. Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide. J Heart Lung Transplant 2019; 38:145.</a></li><li><a class="nounderline abstract_t">Balasubramanian A, Kolb TM, Damico RL, et al. Diffusing Capacity Is an Independent Predictor of Outcomes in Pulmonary Hypertension Associated With COPD. Chest 2020; 158:722.</a></li><li><a class="nounderline abstract_t">Leuchte HH, Baumgartner RA, Nounou ME, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006; 173:744.</a></li><li><a class="nounderline abstract_t">Shorr AF, Davies DB, Nathan SD. Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest 2002; 122:233.</a></li><li><a class="nounderline abstract_t">Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128:2393.</a></li><li><a class="nounderline abstract_t">Strange C, Highland KB. Pulmonary hypertension in interstitial lung disease. Curr Opin Pulm Med 2005; 11:452.</a></li><li><a class="nounderline abstract_t">Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61:68.</a></li><li><a class="nounderline abstract_t">King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164:1171.</a></li><li><a class="nounderline abstract_t">McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126:78S.</a></li><li><a class="nounderline abstract_t">Kimura M, Taniguchi H, Kondoh Y, et al. Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis. Respiration 2013; 85:456.</a></li><li><a class="nounderline abstract_t">Hamada K, Nagai S, Tanaka S, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007; 131:650.</a></li><li><a class="nounderline abstract_t">Song JW, Song JK, Kim DS. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. Respir Med 2009; 103:180.</a></li><li><a class="nounderline abstract_t">Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138:1078.</a></li><li><a class="nounderline abstract_t">Held M, Walthelm J, Baron S, et al. Functional impact of pulmonary hypertension due to hypoventilation and changes under noninvasive ventilation. Eur Respir J 2014; 43:156.</a></li></ol></div><div id="topicVersionRevision">Topic 8258 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36017548" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30545968" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Haemodynamic definitions and updated clinical classification of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22897169" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Haemodynamic effects of non-invasive ventilation in patients with obesity-hypoventilation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24120252" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pulmonary hypertension in obesity-hypoventilation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32747397" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Sleep-related breathing disorders and pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22221973" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pulmonary hypertension due to chronic lung disease: updated Recommendations of the Cologne Consensus Conference 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6110912" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6776858" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3966742" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3922267" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1519845" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Acute effect of oxygen on pulmonary arterial pressure does not predict survival on long-term oxygen therapy in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3605848" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effects of removing oxygen from patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27783918" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3622017" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Noninvasive tests for responsiveness of pulmonary hypertension to oxygen. Prediction of survival in patients with chronic obstructive lung disease and cor pulmonale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2228340" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Role of digoxin in right ventricular failure due to chronic cor pulmonale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7023308" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effect of digoxin on right ventricular function in severe chronic airflow obstruction. A controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25953750" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Management of pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25953750" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Management of pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24355635" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pulmonary hypertension in chronic lung diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26016953" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19118270" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430735" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11035680" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12354470" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17099027" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19875684" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23429918" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18094009" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Sildenafil treatment in COPD does not affect stroke volume or exercise capacity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22360383" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18342559" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18448495" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A randomised, controlled trial of bosentan in severe COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21884013" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6802045" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Reduction in pulmonary hypertension by prostaglandin E1 in decompensated chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8617086" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A placebo-controlled trial of prostacyclin in acute respiratory failure in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19786728" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12668787" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26064454" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24431095" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33440084" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36115497" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34214475" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34214475" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20484178" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20012639" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23732584" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24697923" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26250495" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23648946" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17901413" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21474646" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23682110" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22936711" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27457511" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27067479" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31416769" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22459770" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20595165" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Severe pulmonary hypertension in histiocytosis X: long-term improvement with bosentan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22362861" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26437815" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25078636" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17767746" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pulmonary hypertension associated with sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20560291" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Inhaled iloprost for sarcoidosis associated pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24177203" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11555522" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22858181" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18342757" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29051269" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22988490" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Obesity and pulmonary hypertension: a review of pathophysiologic mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22112678" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Inhaled nitric oxide therapy for secondary pulmonary hypertension with hypertrophic obstructive cardiomyopathy and severe kyphoscoliosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34419372" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9154958" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10694604" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Secondary pulmonary hypertension does not adversely affect outcome after single lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16143242" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Impact of secondary pulmonary hypertension on lung transplant outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7979655" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Impact of pulmonary hypertension on outcome after single-lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16143244" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25444371" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effect of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis after lung transplantation: an analysis of the United Network of Organ Sharing registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20864607" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16093823" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Lung transplantation and interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11722064" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Lung transplantation for primary and secondary pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22975097" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23821503" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Lung transplantation for interstitial lung diseases and pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25430429" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Single versus bilateral lung transplantation: do guidelines exist?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25058363" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Lung transplantation for interstitial lung diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15564022" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Lung transplantation for interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17143366" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Predictors of long-term survival in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16088545" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Cor pulmonale: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8087359" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23018917" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Pulmonary hypertension in COPD: results from the ASPIRE registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7750305" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21556789" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Echocardiographic evidence of pulmonary hypertension is associated with increased 1-year mortality in patients admitted with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33581097" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9872834" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33986032" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Elevated pulmonary vascular resistance predicts mortality in COPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30391191" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32184109" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Diffusing Capacity Is an Independent Predictor of Outcomes in Pulmonary Hypertension Associated With COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16415273" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Brain natriuretic peptide is a prognostic parameter in chronic lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12114364" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Outcomes for patients with sarcoidosis awaiting lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16236900" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Pulmonary hypertension in patients with idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16093821" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Pulmonary hypertension in interstitial lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16227329" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11673205" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249497" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23257350" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17317730" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19097877" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20348196" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23722614" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Functional impact of pulmonary hypertension due to hypoventilation and changes under noninvasive ventilation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
